Preoperative and early postoperative seizures in patients with glioblastoma-two sides of the same coin?
epilepsy
glioblastoma
predictor
survival
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
29
1
2021
Statut:
epublish
Résumé
Symptomatic epilepsy is a common symptom of glioblastoma, which may occur in different stages of disease. There are discrepant reports on association between early seizures and glioblastoma survival, even less is known about the background of these seizures. We aimed at analyzing the risk factors and clinical impact of perioperative seizures in glioblastoma. All consecutive cases with de-novo glioblastoma treated at our institution between 01/2006 and 12/2018 were eligible for this study. Perioperative seizures were stratified into seizures at onset (SAO) and early postoperative seizures (EPS, ≤21days after surgery). Associations between patients characteristics and overall survival (OS) with SAO and EPS were addressed. In the final cohort ( In glioblastoma patients, SAO and EPS seem to have quite different triggers and contrary impact on treatment success and OS. The clinical characteristics of SAO and EPS patients might contribute to the observed survival differences.
Sections du résumé
BACKGROUND
BACKGROUND
Symptomatic epilepsy is a common symptom of glioblastoma, which may occur in different stages of disease. There are discrepant reports on association between early seizures and glioblastoma survival, even less is known about the background of these seizures. We aimed at analyzing the risk factors and clinical impact of perioperative seizures in glioblastoma.
METHODS
METHODS
All consecutive cases with de-novo glioblastoma treated at our institution between 01/2006 and 12/2018 were eligible for this study. Perioperative seizures were stratified into seizures at onset (SAO) and early postoperative seizures (EPS, ≤21days after surgery). Associations between patients characteristics and overall survival (OS) with SAO and EPS were addressed.
RESULTS
RESULTS
In the final cohort (
CONCLUSIONS
CONCLUSIONS
In glioblastoma patients, SAO and EPS seem to have quite different triggers and contrary impact on treatment success and OS. The clinical characteristics of SAO and EPS patients might contribute to the observed survival differences.
Identifiants
pubmed: 33506201
doi: 10.1093/noajnl/vdaa158
pii: vdaa158
pmc: PMC7813191
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa158Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Brain Sci. 2020 Feb 09;10(2):
pubmed: 32050461
Neurosurgery. 2019 Oct 1;85(4):E722-E729
pubmed: 30888031
Neuro Oncol. 2013 Jul;15(7):961-7
pubmed: 23680820
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):504-9
pubmed: 23523186
Neurology. 2011 Sep 20;77(12):1156-64
pubmed: 21880994
Mayo Clin Proc. 2004 Dec;79(12):1489-94
pubmed: 15595331
Neurosurgery. 2017 Nov 1;81(5):824-833
pubmed: 28541497
J Clin Oncol. 2016 Mar 1;34(7):731-9
pubmed: 26786929
Epilepsia. 2006 Dec;47(12):1990-8
pubmed: 17201695
Cancer. 2015 Sep 1;121(17):2926-32
pubmed: 25975354
Oncologist. 2014 Jul;19(7):751-9
pubmed: 24899645
Epilepsy Res. 2017 Feb;130:1-6
pubmed: 28073027
Clin Oncol (R Coll Radiol). 2017 Nov;29(11):739-747
pubmed: 28807361
Seizure. 2019 Jul;69:283-289
pubmed: 31141785
Epilepsia. 2013 Dec;54 Suppl 9:12-7
pubmed: 24328866
Neurology. 2009 Oct 13;73(15):1207-13
pubmed: 19822870
Neurol Med Chir (Tokyo). 2018 Mar 15;58(3):110-115
pubmed: 29343677
Epilepsy Res. 2016 Oct;126:185-96
pubmed: 27513374
J Neurooncol. 2018 Aug;139(1):13-21
pubmed: 29797181
Clin Neurol Neurosurg. 2015 Dec;139:166-71
pubmed: 26489387
Clin Neurol Neurosurg. 2018 Jan;164:75-80
pubmed: 29202377
Acta Neurochir (Wien). 2007 Mar;149(3):245-52; discussion 252-3
pubmed: 17273889
Neurochirurgie. 2020 Jun;66(3):150-154
pubmed: 32278699
J Neurooncol. 2016 Sep;129(3):461-469
pubmed: 27377653
Neuro Oncol. 2013 May;15(5):618-25
pubmed: 23410662
World Neurosurg. 2017 Aug;104:120-128
pubmed: 28512046
PLoS One. 2019 Feb 4;14(2):e0211644
pubmed: 30716120
Seizure. 2012 Apr;21(3):153-9
pubmed: 22300623
Br J Neurosurg. 2012 Jun;26(3):347-54
pubmed: 22168970
Neurosci Lett. 2019 Nov 1;712:134518
pubmed: 31560994
Surg Pract. 2015 Feb;19(1):2-8
pubmed: 26097495
Eur J Cancer. 1998 Jan;34(1):98-102
pubmed: 9624245
J Clin Neurol. 2016 Jan;12(1):21-33
pubmed: 26754778
Am J Hosp Palliat Care. 2017 Aug;34(7):650-653
pubmed: 27151973
Sci Transl Med. 2014 Jul 9;6(244):244ra89
pubmed: 25009229
Neuro Oncol. 2016 May;18(5):700-6
pubmed: 26420896
Front Cell Neurosci. 2015 Oct 21;9:419
pubmed: 26539081
Epilepsia. 2019 Jan;60(1):149-154
pubmed: 30536819
Int J Neurosci. 2012 Apr;122(4):200-8
pubmed: 22082354
Seizure. 2017 Jan;44:93-97
pubmed: 28041673
Epilepsy Res Suppl. 1992;7:197-209
pubmed: 1334663
J Clin Neurosci. 2006 Aug;13(7):747-51
pubmed: 16908158
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Neurosurg. 1997 Sep;87(3):420-30
pubmed: 9285609
Curr Neuropharmacol. 2012 Jun;10(2):124-33
pubmed: 23204982
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Neurol Sci. 2018 Jul 15;390:14-19
pubmed: 29801876
PLoS One. 2016 Jul 20;11(7):e0158206
pubmed: 27438472
Neurol Neurochir Pol. 2018 Aug;52(4):436-447
pubmed: 30122210